Montelukast for Early Life Wheezing

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Lung Diseases, Asthma

In brief

This study will determine the effects of montelukast on the duration of wheezing in children 12 months to 3 years of age who visit a physician for care of a wheezing illness. Only patients from the Ankara area of Hacettepe University Medical Center in Turkey will be included in this study.

Key facts

Study ID

NCT00115297

Run by

University of Massachusetts, Worcester

People needed

62

Starts

2004-09-01

Expected to finish

2016-10-01

Last updated by the study team

2017-03-14

Who can join

Age: 0 and older, up to 3. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Physician-diagnosed wheezing illness

You may not qualify if…

• Asthma
• Prematurity
• Known intolerance to montelukast

Where it is running

• University of Massachusetts/UMass Memorial — Worcester, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.